(Q39847974)

15 September 2017

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). (English)

1 reference

15 September 2017

1 reference

1 reference

N L Steele

1

1 reference

15 September 2017

J A Plumb

2

1 reference

15 September 2017

L Vidal

3

1 reference

15 September 2017

J Tjørnelund

4

1 reference

15 September 2017

P Knoblauch

5

1 reference

15 September 2017

P Buhl-Jensen

6

1 reference

15 September 2017

R Molife

7

1 reference

15 September 2017

R Brown

8

1 reference

15 September 2017

J S de Bono

9

1 reference

15 September 2017

T R J Evans

10

1 reference

15 September 2017

13 August 2010

1 reference

Cancer Chemotherapy and Pharmacology

15 September 2017

1 reference

15 September 2017

67

1 reference

15 September 2017

6

1 reference

15 September 2017

1273-1279

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-010-1419-5

15 September 2017

0 references

cites work

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1419-5

Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1419-5

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1419-5

The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1419-5

Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1419-5

Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1419-5

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1419-5

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1419-5

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1419-5

Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1419-5

10.1007/S00280-010-1419-5

21 January 2018

Identifiers

DOI

1 reference

15 September 2017

1 reference